Independent consultant focused on Market Access, Pricing, and Contracting in US Biopharmaceuticals.

Led pricing and contracting functions in a start-up biotech focused on Medicare Part D Oncology.

•Secured approval of product pricing and contracting strategies
•Fostered relationships with key GPOs in the Gastrointestinal buy-and-bill space
•Designed and built GTN and ASP Models
•Developed pre-launch Market Access Department plan, including spend and FTE hiring ramps
•Co-led 3PL RFP and selection process

• Ophthalmology mAB pipeline assessment (DME, wet AMD) for an investment firm
• Patient Support Service landscape and service assessment for specialty product launch
• Emerging markets infectious disease vaccine ROI assessment/modeling for a large pharma. company
• Global forecast and model development for HIV PrEP asset for a start-up pharma. company

Founded and led the Market Access business unit. Established all key Market Access functions, including trade & distribution, pricing & contracting, patient support & hub services, and EU4+UK access strategy
• Developed the 3-year Commercial Launch Readiness Roadmap and presented to C-suite
• Created and facilitated a 20-person C-suite workshop to develop Pricing Philosophy
• Assessed current Payer and Distribution Landscapes and developed preliminary strategic options

Led market access strategy & capabilities development in a start-up pharmaceutical company
• Secured launch price & price evolution approvals of Dermira’s first product, QBREXA
• Led strategy development of QBREXZA MCO & Government contracting platform. Strategy met all its objectives, including securing 80% national commercial coverage within 6 months post-launch
• Negotiated with customers on net price

Led strategy development for RITUXAN & broader Hematology portfolio worth $5.5B
• Led workstream consisting of vendors & internal team that developed launch price recommendations for RITUXAN HYCELA & VENCLEXTA; gained approval from Genentech, AbbVie, & Biogen leadership
• Developed & gained approval for numerous RITUXAN post-patent loss strategies that will mitigate price & volume erosion across payers, clinics, 340B, non-340B, IDN, FSS

Provided strategic negotiations, analytics, & contracting support MCO account teams
• Supported the Kaiser, CVS, Catamaran, & Anthem account teams
• Assessed contracting strategy in response to Affordable Care Act’s expansion of Medicaid

Pioneered ZS’ relationship with Genentech’s US Pricing division as the first on-site consultant; rapidly grew business with the client from $75K to $550K within one year